Anti-Arbovirus Antibodies Cross-React With Severe Acute Respiratory Syndrome Coronavirus 2

• DOI: 10.1128/spectrum.02639-22
• Publication Date: 2022-11-29T14:02:36Z
• Authors: Taweewun Hunsawong; Darunee Buddhari; Kamonthip Rungroj...; Rungarun Suthangk...; Duangrat Mongkols...; Jindarat Lohachan...; Kedsara Tayong; Kanittha Sirikajo...; Prinyada Rodpradit; Yongyuth Poolpani...; Chonticha Klungthong; Darunee Utennam; Surachai Kaewhiran; Thomas S. Cotrone; Stefan Fernandez; Anthony R. Jones
• Keywords: cross-protection; Immunology; Infectious disease (medical specialty); FOS: Health sciences; Coronavirus Disease 2019 Research; Antibodies, Viral; Microbiology; Dengue virus; Dengue; 03 medical and health sciences; 0302 clinical medicine; Virology; Health Sciences; Humans; Disease; Global Impact of Arboviral Diseases; Biology; Internal medicine; Antibody; SARS-CoV-2; FOS: Clinical medicine; Public Health, Environmental and Occupational Health; Cross-reactivity; COVID-19; Dengue fever; Antibodies, Neutralizing; QR1-502; 3. Good health; serological cross-reactivity; Coronavirus; Coronavirus disease 2019 (COVID-19); arbovirus; Infectious Diseases; Serology; Chikungunya Fever; Medicine; Chikungunya; Cross reactions; Chikungunya virus; Viral Hemorrhagic Fevers and Zoonotic Infections; Research Article

SARS-CoV-2 continues to cause significant morbidity globally, including in areas where DENV and CHIKV are endemic. Reports using rapid diagnostic and ELISAs have demonstrated that serological cross-reactivity between DENV and SARS-CoV-2 can occur.